Latest Healthcare Research Reports

Tag: solid tumor testing market key players

  • Solid Tumor Testing Market Size Projected To Increase From $32.11 Billion To $43.19 Billion During The Forecast Period

    Solid Tumor Testing Market Size Projected To Increase From $32.11 Billion To $43.19 Billion During The Forecast Period

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Solid Tumor Testing Market Size Forecast: How Large Could The Market Become By 2030?

    In the realm of solid tumor diagnostics, a robust expansion has been observed lately, with the market projected to surge from $29.94 billion in 2025 to $32.11 billion by 2026, reflecting a compound annual growth rate of 7.3%. This previous period of growth was propelled by significant developments in cancer detection methodologies, the identification of novel biomarkers, the increased automation within pathology workflows, a heightened general awareness surrounding oncology, and the implementation of various screening programs.

    The market for solid tumor testing is poised for significant expansion over the coming years, projected to reach $43.19 billion by 2030, reflecting a compound annual growth rate of 7.7%. This anticipated surge is fueled by escalating demand for individualized treatment strategies, a heightened emphasis on early disease diagnosis, the broadening application of genomic analyses, the integration of artificial intelligence in diagnostic processes, and a general increase in oncology-focused research initiatives. Key developments expected to shape this market during the forecast period encompass a rise in liquid biopsy utilization, greater adoption of next-generation sequencing technologies, expanded implementation of companion diagnostics, the incorporation of AI in pathological assessments, and a greater prevalence of cancer screening programs.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    Solid Tumor Testing Market Opportunity Drivers: What Is Creating New Revenue Potential?

    The expanding occurrence of cancer is anticipated to be the primary catalyst for the advancement of the solid tumor testing sector in the future. Cancer, characterized by uncontrolled proliferation and dissemination of the body’s abnormal cells, refers to these rogue cells. These aberrant cells, designated as cancer cells, possess the capacity to infiltrate adjacent tissues and organs, and in certain scenarios, to metastasize to distant bodily locations via the circulatory or lymphatic pathways. Constituting approximately 90% of adult cancers, solid tumors represent the predominant form. Solid tumor testing serves the crucial purpose of identifying malignant cells within the bloodstream of individuals afflicted with solid tumors, even at stages where the malignancy remains undetectable through conventional imaging techniques. As an illustration, in July 2024, data sourced from the Australian Institute of Health and Welfare, a governmental entity based in Australia, indicated that in 2023, an estimated 165,000 individuals in Australia received a new cancer diagnosis. This figure translates to a daily incidence exceeding 450 cases, with males accounting for approximately 55% of these newly identified cancers. Consequently, the escalating incidence of cancer is demonstrably fueling the expansion of the solid tumor testing market.

    Solid Tumor Testing Market Segment Analysis: What Are The Major Market Categories?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    Solid Tumor Testing Market Innovation Trends Driving Future Development

    Within the solid tumor testing sector, leading enterprises are concentrating their efforts on advancing novel solutions, specifically liquid biopsy platforms tailored for solid tumor analysis. These platforms involve a range of technologies and methodologies employed to scrutinize bodily fluids, predominantly blood, in pursuit of cancer-associated biomarkers. A case in point is PrognomiQ, a United States-based healthcare firm, which introduced its multi-omics liquid biopsy platform in January of 2023. Following this launch, PrognomiQ has commenced the subsequent phase of its product evolution by initiating a prospective clinical study involving 15,000 participants, with the initial patient having already been enrolled. The impetus behind this undertaking stems from the recognized capacity of multi-omics markers to effectively differentiate between cancerous conditions and non-cancerous controls.

    Solid Tumor Testing Market Leading Companies Driving Competitive Growth

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Access The Complete Solid Tumor Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Solid Tumor Testing Market Regional Distribution: Which Areas Drive Market Expansion?

    North Americawas the largest region in the solid tumor testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Solid Tumor Testing Market Outlook Through 2030 With Analysis Of Industry Trends And Developments

    Solid Tumor Testing Market Outlook Through 2030 With Analysis Of Industry Trends And Developments

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Expected Market Size Of The Solid Tumor Testing Market In 2026 And How Much Will It Reach By 2030?

    The solid tumor testing market has experienced robust expansion in recent years. Projections indicate its value will increase from $29.94 billion in 2025 to $32.11 billion in 2026, driven by a compound annual growth rate (CAGR) of 7.3%. Historically, this growth has been fueled by advances in cancer diagnostics, biomarker discovery, pathology automation, increased oncology awareness, and various screening initiatives.

    The solid tumor testing market is anticipated to experience significant expansion over the coming years. Projections indicate it will reach a valuation of $43.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the projected timeframe include the rising demand for personalized treatments, an increased emphasis on early detection, the expansion of genomic testing, the integration of AI-driven diagnostics, and the ongoing advancements in oncology research. Key trends expected during this period encompass the rise of liquid biopsy testing, the wider adoption of next-generation sequencing, the broadening scope of companion diagnostics, the incorporation of AI-based pathology, and an increase in screening initiatives.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    What Major Growth Factors Are Impacting The Solid Tumor Testing Market?

    The rising incidence of cancer is projected to propel the expansion of the solid tumor testing market in the coming years. Cancer is a medical condition defined by the unrestrained growth and spread of abnormal cells within the body. These anomalous cells, known as cancer cells, can invade neighboring tissues and organs and, in certain cases, travel to other body areas via the bloodstream or lymphatic system. A significant majority, approximately 90%, of adult cancers are solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients with solid tumors, even when the cancer is not yet visible on imaging examinations. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, and males constituted about 55% of these diagnoses. Thus, the increasing prevalence of cancer is a primary driver for the growth of the solid tumor testing market.

    What Segment Types Are Included In The Solid Tumor Testing Market Analysis?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    What Trends Are Affecting The Growth Of The Solid Tumor Testing Market?

    Companies operating within the solid tumor cancer treatment market are focusing on advancing immunotherapies, targeted therapies, and cell-based treatments to enhance patient outcomes and broaden therapeutic options. For instance, in July 2025, Dispatch Bio, a US-based biotechnology company, initiated operations to develop universal treatments for solid tumors. The firm intends to advance new therapeutic approaches designed to target a wide variety of solid tumor types, improve efficacy across different patient populations, and accelerate the development of scalable cancer immunotherapies, with the potential to transform standard-of-care treatment and improve long-term survival rates.

    Who Are The Prominent Players Across The Solid Tumor Testing Market?

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Access The Complete Solid Tumor Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Region Is The Primary Market For The Solid Tumor Testing Market?

    North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Solid Tumor Testing Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

    Cancer Diagnostics Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Solid Tumor Cancer Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

    Hemato Oncology Testing Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Multi-Omics Liquid Biopsy Innovations Transforming Solid Tumor Testing Market

    Multi-Omics Liquid Biopsy Innovations Transforming Solid Tumor Testing Market

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Projected Increase In Market Value Of The Solid Tumor Testing Market During 2026–2030?

    The solid tumor testing market has experienced robust growth in recent years. It is projected to expand from $29.94 billion in 2025 to $32.11 billion in 2026, showing a compound annual growth rate (CAGR) of 7.3%. The growth witnessed in the past can be attributed to advancements in cancer diagnostics, the discovery of biomarkers, automation in pathology, increased oncology awareness, and various screening initiatives.

    The solid tumor testing market size is predicted to undergo significant expansion in the coming years. Its value is projected to reach $43.19 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This forecasted growth can be attributed to the rising demand for personalized treatments, a stronger focus on early detection, the broadening scope of genomic testing, the advent of AI-driven diagnostics, and an overall increase in oncology research. Prominent trends anticipated in this period include the proliferation of liquid biopsy testing, the widespread adoption of next-generation sequencing, the growth of companion diagnostics, the incorporation of AI-based pathology, and the expansion of screening programs.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    Which Drivers Are Supporting The Solid Tumor Testing Market Growth?

    The anticipated rise in cancer prevalence is poised to drive the expansion of the solid tumor testing market in the future. Cancer refers to a medical condition characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body. Such aberrant cells, termed cancer cells, possess the ability to infiltrate adjacent tissues and organs, occasionally metastasizing to distant bodily regions via the circulatory or lymphatic systems. Approximately 90% of adult cancer diagnoses manifest as solid tumors. Solid tumor testing serves to identify cancer cells present in the bloodstream of individuals afflicted with solid tumors, even when these tumors are not yet detectable through imaging examinations. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that an estimated 165,000 Australians received a new cancer diagnosis in 2023, translating to over 450 new cases daily, with males constituting about 55% of these diagnoses. Consequently, the growing incidence of cancer is fueling the expansion of the solid tumor testing market.

    How Is The Solid Tumor Testing Market Categorized Across Its Segment Groups?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    Which Trends Are Expected To Impact The Solid Tumor Testing Market?

    Leading companies in the solid tumor testing market are primarily focused on developing innovative solutions, such as liquid biopsy platforms for solid tumor testing. A liquid biopsy platform integrates various technologies and systems designed to analyze body fluids, predominantly blood, to identify cancer-related biomarkers. For example, in January 2023, PrognomiQ, a US-based healthcare firm, introduced its multi-omics liquid biopsy platform. PrognomiQ has since initiated the next phase of its product development by commencing a prospective clinical program with 15,000 subjects, with the first patient already enrolled. This undertaking was prompted by the potential for multi-omics markers to effectively differentiate between cancer and control cases.

    Which Firms Are Influencing Competition In The Solid Tumor Testing Market?

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Get The Full Solid Tumor Testing Market Report:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Region Dominates The Solid Tumor Testing Market By Market Share?

    North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Solid Tumor Testing Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

    Cancer Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Solid Tumor Cancer Treatment Market Report

    https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

    Hemato Oncology Testing Market Report

    https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Solid Tumor Testing Market Size Outlook and Demand Growth Across 2026–2030

    Solid Tumor Testing Market Size Outlook and Demand Growth Across 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Much Is The Solid Tumor Testing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

    The solid tumor testing market size has experienced robust expansion in recent years. This market is projected to expand from $29.94 billion in 2025 to $32.11 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.3%. Historically, this growth has been driven by advances in cancer diagnostics, biomarker discovery, pathology automation, oncology awareness, and screening initiatives.

    The solid tumor testing market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $43.19 billion, exhibiting a compound annual growth rate (CAGR) of 7.7%. This forecasted development is primarily driven by factors such as the increasing demand for personalized treatments, a heightened focus on early detection, the expansion of genomic testing, the emergence of AI-driven diagnostics, and the overall growth in oncology research. Key trends expected during this period involve the rising prevalence of liquid biopsy testing, wider adoption of next-generation sequencing, the broadening scope of companion diagnostics, the integration of AI in pathology, and an increase in screening initiatives.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    What Drivers Are Influencing The Solid Tumor Testing Market?

    The anticipated rise in cancer cases is projected to drive the expansion of the solid tumor testing market in the future. Cancer is characterized by the uncontrolled proliferation and dissemination of aberrant cells within the body. These malignant cells, referred to as cancer cells, possess the ability to infiltrate nearby tissues and organs, sometimes spreading to other parts of the body through the bloodstream or lymphatic system. A significant majority, approximately 90%, of adult cancers are solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients with solid tumors, even if the cancer is not yet visible on imaging tests. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the increasing prevalence of cancer is driving the growth of the solid tumor testing market.

    What Major Segment Divisions Exist Within The Solid Tumor Testing Market?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    What Trends Are Affecting The Expansion Of The Solid Tumor Testing Market?

    Companies operating in the solid tumor testing market are focusing on developing innovations such as liquid biopsy platforms for solid tumor testing. A liquid biopsy platform includes various technologies and systems used to analyze body fluids, typically blood, for cancer-related biomarkers. For instance, in January 2023, PrognomiQ, a US-based healthcare company, launched its multi-omics liquid biopsy platform. PrognomiQ’s next phase of product development has begun with the initiation of a 15,000-subject prospective clinical program, which has enrolled its first patient. This initiative was spurred by the potential of multi-omics markers to distinguish between cancer and controls.

    Which Companies Are Leading Innovation In The Solid Tumor Testing Market?

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Read the full solid tumor testing market report here:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Regions Are Expected To Experience Rapid Expansion In The Solid Tumor Testing Market?

    North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Solid Tumor Testing Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

    Cancer Diagnostics Global Market Report

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Solid Tumor Cancer Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

    Hemato Oncology Testing Global Market Report

    https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Solid Tumor Testing Market Performance Outlook 2026–2030: Revenue to Hit $43.19 Billion at 7.7% CAGR

    Solid Tumor Testing Market Performance Outlook 2026–2030: Revenue to Hit $43.19 Billion at 7.7% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the solid tumor testing market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Solid Tumor Testing Market in 2030?

    The solid tumor testing market has shown considerable expansion in recent years. It is anticipated to increase from $29.94 billion in 2025 to $32.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. Historically, this market’s growth has been fueled by progress in cancer diagnostics, the discovery of biomarkers, automation in pathology, increased oncology awareness, and various screening programs.

    The market for solid tumor testing is projected to experience robust expansion over the coming years. This market is anticipated to reach $43.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the projected period include the rising demand for personalized treatments, a greater emphasis on early detection, the broader application of genomic testing, the emergence of AI-driven diagnostics, and the expansion of oncology research. Key trends expected within the forecast timeframe encompass the proliferation of liquid biopsy testing, the uptake of next-generation sequencing, the wider availability of companion diagnostics, the incorporation of AI into pathology, and an increase in screening initiatives.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    What Drivers Are Influencing Production Trends In The Solid Tumor Testing Market?

    The escalating incidence of cancer is anticipated to propel the expansion of the solid tumor testing market in the future. Cancer is a medical condition defined by the uncontrolled proliferation and spread of abnormal cells throughout the body. These aberrant cells, known as cancer cells, possess the ability to invade adjacent tissues and organs and, in certain instances, to disseminate to other parts of the body via the bloodstream or lymphatic system. A significant majority, approximately 90%, of adult cancers are classified as solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients diagnosed with solid tumors, even before the cancer becomes visible on imaging scans. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males constituting about 55% of these diagnoses. Therefore, the rising prevalence of cancer is a primary driver for the growth of the solid tumor testing market.

    Which Segment Groups Are Influencing The Solid Tumor Testing Market?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    Which Market Trends Are Opening Growth Opportunities In The Solid Tumor Testing Market?

    Major companies engaged in the solid tumor testing market are prioritizing advancements, specifically liquid biopsy platforms for solid tumor analysis. A liquid biopsy platform utilizes diverse technologies and systems to examine bodily fluids, typically blood, for biomarkers associated with cancer. For example, in January 2023, PrognomiQ, a US-based healthcare firm, unveiled its multi-omics liquid biopsy platform. PrognomiQ has advanced its product development with the launch of a 15,000-subject prospective clinical program, which has already welcomed its first patient. This effort was motivated by the potential of multi-omics markers to differentiate between cancer cases and control groups.

    Who Are The Top-Performing Companies In The Solid Tumor Testing Market In Recent Years?

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Region Currently Holds The Largest Share Of The Solid Tumor Testing Market?

    North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Solid Tumor Testing Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

    Hemato Oncology Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

    Cancer Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Solid Tumor Cancer Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Solid Tumor Testing Market Performance Outlook 2026–2030: Revenue to Hit $43.19 Billion at 7.7% CAGR

    Solid Tumor Testing Market Performance Outlook 2026–2030: Revenue to Hit $43.19 Billion at 7.7% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the solid tumor testing market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Solid Tumor Testing Market in 2030?

    The solid tumor testing market has shown considerable expansion in recent years. It is anticipated to increase from $29.94 billion in 2025 to $32.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. Historically, this market’s growth has been fueled by progress in cancer diagnostics, the discovery of biomarkers, automation in pathology, increased oncology awareness, and various screening programs.

    The market for solid tumor testing is projected to experience robust expansion over the coming years. This market is anticipated to reach $43.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the projected period include the rising demand for personalized treatments, a greater emphasis on early detection, the broader application of genomic testing, the emergence of AI-driven diagnostics, and the expansion of oncology research. Key trends expected within the forecast timeframe encompass the proliferation of liquid biopsy testing, the uptake of next-generation sequencing, the wider availability of companion diagnostics, the incorporation of AI into pathology, and an increase in screening initiatives.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    What Drivers Are Influencing Production Trends In The Solid Tumor Testing Market?

    The escalating incidence of cancer is anticipated to propel the expansion of the solid tumor testing market in the future. Cancer is a medical condition defined by the uncontrolled proliferation and spread of abnormal cells throughout the body. These aberrant cells, known as cancer cells, possess the ability to invade adjacent tissues and organs and, in certain instances, to disseminate to other parts of the body via the bloodstream or lymphatic system. A significant majority, approximately 90%, of adult cancers are classified as solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients diagnosed with solid tumors, even before the cancer becomes visible on imaging scans. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males constituting about 55% of these diagnoses. Therefore, the rising prevalence of cancer is a primary driver for the growth of the solid tumor testing market.

    Which Segment Groups Are Influencing The Solid Tumor Testing Market?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    Which Market Trends Are Opening Growth Opportunities In The Solid Tumor Testing Market?

    Major companies engaged in the solid tumor testing market are prioritizing advancements, specifically liquid biopsy platforms for solid tumor analysis. A liquid biopsy platform utilizes diverse technologies and systems to examine bodily fluids, typically blood, for biomarkers associated with cancer. For example, in January 2023, PrognomiQ, a US-based healthcare firm, unveiled its multi-omics liquid biopsy platform. PrognomiQ has advanced its product development with the launch of a 15,000-subject prospective clinical program, which has already welcomed its first patient. This effort was motivated by the potential of multi-omics markers to differentiate between cancer cases and control groups.

    Who Are The Top-Performing Companies In The Solid Tumor Testing Market In Recent Years?

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Region Currently Holds The Largest Share Of The Solid Tumor Testing Market?

    North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Solid Tumor Testing Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

    Hemato Oncology Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

    Cancer Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Solid Tumor Cancer Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Solid Tumor Testing Market Performance Outlook 2026–2030: Revenue to Hit $43.19 Billion at 7.7% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the solid tumor testing market from 2026–2035 with trusted insights from The Business Research Company

    What total market size is anticipated for the Solid Tumor Testing Market in 2030?

    The solid tumor testing market has shown considerable expansion in recent years. It is anticipated to increase from $29.94 billion in 2025 to $32.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. Historically, this market’s growth has been fueled by progress in cancer diagnostics, the discovery of biomarkers, automation in pathology, increased oncology awareness, and various screening programs.

    The market for solid tumor testing is projected to experience robust expansion over the coming years. This market is anticipated to reach $43.19 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the projected period include the rising demand for personalized treatments, a greater emphasis on early detection, the broader application of genomic testing, the emergence of AI-driven diagnostics, and the expansion of oncology research. Key trends expected within the forecast timeframe encompass the proliferation of liquid biopsy testing, the uptake of next-generation sequencing, the wider availability of companion diagnostics, the incorporation of AI into pathology, and an increase in screening initiatives.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    What Drivers Are Influencing Production Trends In The Solid Tumor Testing Market?

    The escalating incidence of cancer is anticipated to propel the expansion of the solid tumor testing market in the future. Cancer is a medical condition defined by the uncontrolled proliferation and spread of abnormal cells throughout the body. These aberrant cells, known as cancer cells, possess the ability to invade adjacent tissues and organs and, in certain instances, to disseminate to other parts of the body via the bloodstream or lymphatic system. A significant majority, approximately 90%, of adult cancers are classified as solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients diagnosed with solid tumors, even before the cancer becomes visible on imaging scans. For instance, in July 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that an estimated 165,000 Australians were newly diagnosed with cancer in 2023, which corresponds to over 450 cases each day, with males constituting about 55% of these diagnoses. Therefore, the rising prevalence of cancer is a primary driver for the growth of the solid tumor testing market.

    Which Segment Groups Are Influencing The Solid Tumor Testing Market?

    The solid tumor testing market covered in this report is segmented –

    1) By Type: Genetic Testing, Conventional Testing

    2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer

    3) By Application: Clinical, Research

    4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

    Which Market Trends Are Opening Growth Opportunities In The Solid Tumor Testing Market?

    Major companies engaged in the solid tumor testing market are prioritizing advancements, specifically liquid biopsy platforms for solid tumor analysis. A liquid biopsy platform utilizes diverse technologies and systems to examine bodily fluids, typically blood, for biomarkers associated with cancer. For example, in January 2023, PrognomiQ, a US-based healthcare firm, unveiled its multi-omics liquid biopsy platform. PrognomiQ has advanced its product development with the launch of a 15,000-subject prospective clinical program, which has already welcomed its first patient. This effort was motivated by the potential of multi-omics markers to differentiate between cancer cases and control groups.

    Who Are The Top-Performing Companies In The Solid Tumor Testing Market In Recent Years?

    Major companies operating in the solid tumor testing market are Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company BD, Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Anixa Biosciences Inc., Cellular Biomedicine Group

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Region Currently Holds The Largest Share Of The Solid Tumor Testing Market?

    North America was the largest region in the solid tumor testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Solid Tumor Testing Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2026, By The Business Research Company

    Hemato Oncology Testing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/hemato-oncology-testing-global-market-report

    Cancer Diagnostics Market Report 2026

    https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

    Solid Tumor Cancer Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • What Is The Forecast Valuation Of The Global Solid Tumor Testing Market Projected To Reach $39.95 Billion By 2029?

    What Is The Forecast Valuation Of The Global Solid Tumor Testing Market Projected To Reach $39.95 Billion By 2029?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    What Are The Future Growth Projections For The Solid Tumor Testing Market Size?

    In recent times, the market size of solid tumor testing has seen considerable expansion. It is projected to increase from $27.96 billion in 2024 to $29.94 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 7.1%. Factors contributing to this growth during the historic period can be associated with precision medicine, ineffective tumor-specific drug delivery, suboptimal therapeutic efficacy, high costs, and reductionist methods applied to cancer chemotherapies.

    The market size for solid tumor testing is projected to experience significant expansion in the upcoming years, expected to rise to $39.95 billion by 2029, with a compounded annual growth rate (CAGR) of 7.5%. This projected growth during the forecast period can be linked to the rising prevalence of cancer, enhancement in healthcare infrastructure, the advent of AI and IoT-based diagnostic tools, and escalated government initiatives. The forecast period also forecasts breakthroughs in diagnostic tools, the launch of nanocarrier-based treatment, strategic collaborations, and next-generation testing equipment.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    Which Factors Are Steering Growth In The Solid Tumor Testing Market?

    The solid tumor testing market is predicted to grow due to the increasing prevalence of cancer. The malady of cancer characterizes the uncontrolled growth and spread of rogue cells in our bodies. These rogue cells, often referred to as cancer cells, have the tendency to invade neighboring tissues and organs. In certain instances, they can even spread to other regions of the body via the bloodstream or the lymphatic system. About 90% of adult cancers are solid tumors. Solid tumor testing aids in the detection of these cancerous cells in a patient’s blood, even if the cancer is not noticeably present on any imaging test. For example, a report published by the Centers for Disease Control and Prevention (a national public health agency based in the US), in June 2023 showed that there were 1,603,844 new cases of cancer and 602,347 cancer-related deaths in the US in 2020. In addition, for every 100,000 people, there were 403 new cases of cancer and 144 cancer-related deaths. Thus, the increasing incidence of cancer is fueling the expansion of the solid tumor testing market.

    How Is The Solid Tumor Testing Market Organized By Different Segments?

    The solid tumor testingmarket covered in this report is segmented –

    1) By Type: Genetic Testing; Conventional Testing

    2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer

    3) By Application: Clinical; Research

    4) By End-Users: Hospitals; Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology; Cytology; Imaging Techniques

    What Current And Upcoming Trends Are Shaping The Solid Tumor Testing Market?

    The emergence of advanced liquid biopsy test solutions is a significant trend in the solid tumor testing market. Prominent firms in the market are concentrating on creating these cutting-edge liquid biopsy tests to consolidate their market stance and gain a competitive edge. Take, for example, NeoGenomics Inc., a leading laboratory company from the US. In June 2020, they rolled out a comprehensive collection of three liquid biopsy tests for solid tumors for cancer patients. These pioneering tests have the ability to identify cancer cells in the blood of patients with solid tumors, even when the cancer is not detected via imaging tests. These tests can guide doctors on any further testing or treatment required. Moreover, these tests are non-invasive, facilitate early detection, can be tailored for individual treatment, and have FDA approval. They feature a turnaround time of seven days or less, which can greatly reduce the time physicians spend waiting for results.

    Who Are The Most Influential Companies In The Solid Tumor Testing Market?

    Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    Which Region Dominates The Solid Tumor Testing Market Today?

    North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2025, By The Business Research Company

    Tumor Ablation Therapy Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

    Tumor Embolization Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    Testing Software Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/testing-software-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Solid Tumor Testing Industry Trends: Where the Market Is Headed by 2029

    Global Solid Tumor Testing Industry Trends: Where the Market Is Headed by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Is The Solid Tumor Testing Market Size Likely To Evolve From 2025 Through 2034?

    The solid tumor testing market has experienced robust expansion in recent years. Forecasts indicate it will expand from $27.96 billion in 2024 to $29.94 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. Historically, this growth has been driven by factors such as the adoption of personalized or precision medicine, challenges in tumor-selective drug delivery, limited therapeutic efficacy, high unsustainable costs, and reductionist methods in cancer chemotherapies.

    The solid tumor testing market is projected to experience substantial expansion over the upcoming years, with its size anticipated to reach $39.95 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.5%. This growth throughout the forecast period is primarily driven by the rising incidence of cancer, improvements in healthcare infrastructure, the advent of AI and IoT-driven diagnostic tools, and increasing government initiatives. Key trends identified for the forecast period encompass significant advancements in diagnostic technologies, the introduction of nanocarrier-based therapeutic approaches, various strategic collaborations, and the development of next-generation testing devices.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    Which Drivers Are Impacting The Solid Tumor Testing Market?

    The expanding occurrence of cancer is anticipated to drive the solid tumor testing market’s future growth. Cancer is a condition characterized by the uncontrolled proliferation and dissemination of abnormal cells in the body. These malignant cells, known as cancer cells, can invade nearby tissues and organs, and may spread to other parts of the body through the bloodstream or lymphatic system. About 90% of adult cancers are solid tumors. Solid tumor testing is employed to detect cancer cells in the blood of patients with solid tumors, even when the cancer is not yet apparent on imaging tests. For example, a June 2023 report from the Centers for Disease Control and Prevention, a US-based national public health agency, stated that in 2020, there were 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US, with 403 new cancer cases and 144 cancer-related deaths reported for every 100,000 people. Thus, the escalating prevalence of cancer is fueling the expansion of the solid tumor testing market.

    What Are The Primary Types Of Segments Analyzed In The Solid Tumor Testing Market?

    The solid tumor testingmarket covered in this report is segmented –

    1) By Type: Genetic Testing; Conventional Testing

    2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer

    3) By Application: Clinical; Research

    4) By End-Users: Hospitals; Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology; Cytology; Imaging Techniques

    What Trends Are Redefining The Solid Tumor Testing Market Dynamics?

    Innovative liquid biopsy test solutions represent a significant trend gaining traction in the solid tumor testing market. Major companies operating within this market are concentrating on developing advanced liquid biopsy test solutions to fortify their position and secure a competitive advantage. For instance, in June 2020, NeoGenomics Inc., a US-based testing laboratory company, launched its extensive collection of three solid tumor liquid biopsy tests for cancer patients. These cutting-edge tests are designed to identify cancer cells in the blood of individuals with solid tumors, even when the cancer is not yet visible through imaging. The tests can aid doctors in determining subsequent testing or treatment options. Additionally, they are non-invasive, facilitate early detection, enable personalized treatment, and hold FDA approval. Furthermore, these three new tests boast turnaround times of seven days or fewer, thereby saving clinicians a substantial amount of time.

    Who Are The Top Performing Companies In The Solid Tumor Testing Market In Recent Years?

    Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    What Regional Growth Trends Are Shaping The Solid Tumor Testing Market Outlook?

    North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Request A Customized Version Of The Solid Tumor Testing Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Browse Through More Reports Similar to the Global Solid Tumor Testing Market 2025, By The Business Research Company

    Tumor Ablation Therapy Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/tumor-ablation-therapy-devices-global-market-report

    Tumor Embolization Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

    Testing Software Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/testing-software-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • From Insight to Impact: Strategic Growth Mapping in the Solid Tumor Testing Market

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has The Solid Tumor Testing Market Growth Evolved From 2024 To 2025, And What’s Ahead?

    In recent times, the market size for solid tumor testing has witnessed robust growth. From 2024 to 2025, the market is projected to increase from $27.96 billion to $29.94 billion, indicating a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth during the historic period include the rise of personalized or precision medicine, ineffective tumor-selective drug delivery, the lack of therapeutic efficacy, unsustainable expenses, and reductive strategies towards cancer chemotherapies.

    The market for solid tumor testing is projected to experience significant expansion in the coming years, with a predicted value of $39.95 billion in 2029, reflecting a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this anticipated growth include a higher incidence of cancer, improved healthcare facilities, the introduction of AI and IoT-based diagnostic tools, along with increasing government initiatives. Noteworthy trends for the forecast period encompass progress in diagnostic devices, the arrival of therapies using nanocarriers, strategic partnerships, and the development of next-generation testing equipment.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

    What are the Fundamental Drivers and Innovations Shaping the Solid Tumor Testing Market?

    The escalating rates of cancer are anticipated to fuel the expansion of the solid tumor testing market. Cancer is a disease characterized by abnormal cell growth and proliferation in the body. These irregular cells, referred to as cancer cells, have the potential to infiltrate nearby tissues and organs, and sometimes can even migrate to other bodily parts via the bloodstream or lymphatic system. Nearly 90% of cancers in adults are solid tumors. Solid tumor testing is utilized to identify cancer cells in the bloodstream of patients with solid tumors, even before the cancer can be detected through imaging tests. For example, a report from the Centers for Disease Control and Prevention, a national public health organization based in the US, revealed that in June 2023, there were 1,603,844 new cancer incidences and 602,347 cancer-induced fatalities in the US in 2020, with 403 fresh cancer diagnoses and 144 cancer-linked fatalities reported per 100,000 individuals. Hence, the rising incidence of cancer is boosting the growth of the solid tumor testing market.

    How Is the Solid Tumor Testing Market Segmented?

    The solid tumor testingmarket covered in this report is segmented –

    1) By Type: Genetic Testing; Conventional Testing

    2) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Cervical Cancer

    3) By Application: Clinical; Research

    4) By End-Users: Hospitals; Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic Research Institutions

    Subsegments:

    1) By Genetic Testing: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Fluorescence In Situ Hybridization (FISH)

    2) By Conventional Testing: Histopathology; Cytology; Imaging Techniques

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=12658&type=smp

    Which Regions Are Driving the Next Phase of the Solid Tumor Testing Market Growth?

    North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    What Key Trends Are Shaping the Future of the Solid Tumor Testing Market?

    Creative liquid biopsy test solutions are emerging as a significant trend in the solid tumor testing market. Major companies in this market are concentrating on developing these innovative solutions to enhance their market position and secure a competitive edge. For example, NeoGenomics Inc., a US-based testing lab, rolled out a comprehensive set of three liquid biopsy tests for solid tumor in June 2020. These cutting-edge tests are formulated to identify cancer cells in patients’ blood, even before these tumors are detectable in imaging tests. These tests aid healthcare professionals in choosing further tests or treatments. The benefits of these tests include non-invasiveness, early detection, tailor-made treatment plans, and they also have FDA approval. Additionally, with a turnaround time of seven days or less, these three new tests save a substantial amount of time for doctors.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

    How Is the Solid Tumor Testing Market Defined and What Are Its Core Parameters?

    Solid tumor testing refers to the diagnostic and molecular testing conducted on solid tumors, which are masses or growths of abnormal cells that form in various body tissues. Solid tumor testing is used to detect cancer cells or cancer-related DNA in patients’ blood with solid tumors, even if the cancer is not yet visible on imaging tests.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12658

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model